Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon in early stage Parkinson's disease
NCT02847650Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of tavapadon in Parkinson's disease (PD), sponsored by Pfizer. Started Oct 2016; status: terminated.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02847650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02847650.